We would like to thank our shareholders for their continued support.

In Japan, sales of Nutrition Products' focused business of Closed Drug Mixing/Infusion Sets with Needleless Access Port and Blood Bags with Lukocyte Reduction Filter remained strong, while sales of Nutrition Sets, Medical Gloves, and Hemodialysis Machines declined. On the other hand, sales of nutrition sets, medical gloves, and Hemodialysis Machines declined. Overseas, although the situation differs from country to country and region to region, sales of mainstay Apheresis Kit, Blood Bags, and Hemodialysis Machines for China increased due to the revitalization of the market by the recovery of medical demand, and the yen depreciation of the yen also contributed to the increase in yen equivalent value, boosting sales.

As a result, net sales for the second quarter increased 1,272 million yen year on year to 31,248 million yen (up 4.2% year on year).

As for profits, despite the effect of increased sales, operating loss was 320 million yen (vs. an operating loss of 44 million yen in the same period of the previous year) due to soaring costs of raw materials and electricity, as well as increased labor costs in preparation for increased demand, and increased R&D expenses. In addition, due to equity in earnings of affiliates and foreign exchange gains, ordinary loss was 135 million yen (ordinary income of 56 million yen in the same period of the previous year), and after income taxes, net loss attributable to owners of the parent was 258 million yen (net loss attributable to owners of the parent of 68 million yen in the same period of the previous year) Net sales and operating income (loss)

In accordance with our basic policy on profit distribution, we have decided to pay a dividend of 8.5 yen per share.

As a bridge between people and medicine, JMS will continue to create and provide "value" in the medical field in each country and region, and contribute to improving the quality of medical care and people's lives worldwide, while enhancing corporate value through sound business activities.

We would like to ask our shareholders for their continued support and cooperation.

December 2023